ClinicalTrials.gg
CompletedNCT00452530ADVANCE-2Updated Jul 9, 2014Results posted

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

A Phase 3 interventional study of Enoxaparin and Apixaban in Deep Vein Thrombosis and Pulmonary Embolism, sponsored by Bristol-Myers Squibb. Completed at 122 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-09.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,221
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing apixaban in Venous Thrombosis — 5 open to participants now, 6 under way, 1 of them phase 3. apixaban · Venous Thrombosis.

Enrollment
5th of 26
3,221 · median 445
Started
2007
with 1 other
Phase 3
10 of 26
1 open now
Registered
3rd of 26
by date
Lead sponsor
6 of 26
Bristol-Myers Squibb

Among the 26 studies testing apixaban in Venous Thrombosis, this one is the 5th largest by enrollment, is one of 2 that started in 2007, is one of 10 in phase 3, and was the 3rd registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

5 of the 26 studies testing apixaban in Venous Thrombosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing apixaban in Venous Thrombosis, or all of them as a file.
02

Study summary

The purpose of this study is to learn whether apixaban prevents the development of blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism), which sometimes occur after knee replacement surgery, and to compare the efficacy of apixaban with that of enoxaparin (Lovenox®) in the prevention of these clots. The safety of apixaban will also be studied.

03

Conditions studied

  • Deep Vein Thrombosis
  • Pulmonary Embolism

Keywords

  • Prevention of deep vein thrombosis and pulmonary embolism after total knee replacement surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  • Patients scheduled for either elective unilateral or same-day bilateral total knee replacement surgery (TKR) or a revision of at least 1 component of a TKR
  • Patients willing and able to undergo bilateral ascending contrast venography

Key Exclusion Criteria

  • Known or suspected hereditary or acquired bleeding or coagulation disorders in the participant or his or her first-degree relative
  • Known or suspected history of heparin-induced thrombocytopenia
  • Known coagulopathy
  • Active bleeding or at high risk for bleeding
  • Brain, spinal, ophthalmologic, or major surgery or trauma within the past 90 days
  • Active hepatobiliary disease
  • Alcohol and/or substance abuse within the past year
  • Any condition for which, in the opinion of the investigator, surgery or administration of an anticoagulant was
  • Two consecutive blood pressure readings within 15 to 30 minutes with supine systolic blood pressure >180 mm Hg or supine diastolic blood pressure >105 mm Hg
  • laboratory abnormalities at the enrollment visit:

    • \<10 g/dL
    • count \<100,000/mm\^3
    • \<30 mL/min, as estimated by the method of Cockcroft and Gault
    • or aspartate aminotransferase level >2* (ULN) or a total ≥1.5*ULN (unless an alternative causative factor such as Gilbert's syndrome was identified)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
3,221 participants (actual)

Study arms

  • Experimental
    Apixaban, 2.5 mg BID + Placebo

    Participants received apixaban, 2.5-mg tablets twice daily (BID), plus a matching enoxaparin-placebo injection 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.

    Drug: Apixaban · Drug: Enoxaparin-matching placebo

  • Active comparator
    Enoxaparin, 40 mg QD + Placebo

    Participants received enoxaparin, 40-mg subcutaneous injection once daily (QD), plus a matching apixaban-placebo tablet 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.

    Drug: Enoxaparin · Drug: Apixaban-matching placebo

Interventions

  • 40 mg, administered once daily by subcutaneous injection, for 12 days

    Also known as: Lovenox®

  • 2.5 mg, administered twice daily as tablets, for 12 days

    Also known as: BMS-562247

  • DrugEnoxaparin-matching placebo

    Administered once daily by subcutaneous injection

  • DrugApixaban-matching placebo

    Oral tablet administered twice daily

06

What researchers measure

Primary outcomes

  1. Rate of Adjudicated Venous Thromboembolic Event-related and All-cause Deaths With Onset During the Intended-treatment Period

    Event rate=Number of events divided by the number of patients evaluated. Intended treatment period starts on the day of randomization, and for those who received study drug, ends at the later of 2 days after last dose or 14 days after the first dose of study drug; for randomized patients who did not receive study drug, the period ends 14 days after randomization.Venous thromboembolic event (VTE)=nonfatal pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), or asymptomatic proximal DVT detected by ultrasound. VTE-related death=fatal PE or sudden death for which VTE could not be excluded as a cause.

    Time frame: Day of randomization to later of 2 days after last dose or 14 days after first dose; 14 days after randomization for those who did not receive study drug

Secondary outcomes

  1. Rate of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During the Intended Treatment Period

    Event rate=Number of events divided by the number of patients evaluated. Intended treatment period starts on the day of randomization, and for those who received study drug, ends at the later of 2 days after last dose or 14 days after the first dose of study drug; for randomized patients who did not receive study drug, the period ends 14 days after randomization; for randomized patients who did not receive study drug, the period ends 14 days after randomization. Venous thromboembolic event (VTE)=nonfatal pulmonary embolism (PE), symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death=fatal PE or sudden death for which VTE could not be excluded as a cause.

    Time frame: Day of randomization to later of 2 days after last dose or 14 days after first dose; 14 days after randomization for those who did not receive study

  2. Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), and Major Bleeding or CRNM

    Event rate=Number of events divided by number of patients evaluated. Adjusted difference of event rates takes into consideration type of surgery as a stratification factor. Bleeding Criteria: Major bleeding=an event consisting of clinically overt bleeding accompanied by a decrease in hemoglobin of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. CRNM bleeding= clinically overt bleeding; that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event; that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding; or a change in antithrombic treatment.

    Time frame: Days 1 to 12

  3. Number of Participants With Serious Adverse Events (SAE), Bleeding Adverse Events (AEs), Discontinuations Due to AEs, and Death as Outcome

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Bleeding AEs=all serious or nonserious bleeding-related AEs.

    Time frame: Days 1 through 12 + 2 days (nonserious AEs, bleeding AES) or 30 days (SAES, deaths) after last dose of study drug

Other outcomes

  1. Summary of Laboratory Marked Abnormalities on Hematology and Liver and Kidney Function Test Results During the Treatment Period (Patients With Available Measurements)

    preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal; abs=absolute. Hemoglobin (g/dL): \>2 decrease from preRx value or value \<=8; hematocrit (%): \<0.75\*preRx; platelets: \<100\*10\^9 cells/L; erythrocytes (\*10\^6 cells/μL): \<0.75\*preRx; leukocytes: \<0.75\*LLN or \>1.25\*ULN, or if preRx \<LLN, use \<0.8\*preRx or \>ULN if preRx \>ULN use \>1.2\*preRx or \<LLN; abs basophils: \>400/mm\^3; abs eosinophils: \> 0.750\*10\^3 cells/µL; abs lymphocytes: \<0.750\*10\*3 cells/ µL or \>7.50\*10\^3 c/ µL; abs monocytes \> 2000/mm\^3; abs neutrophils: \<1.0\*10\^3 cells/μL; ALP (U/L): \>2\*ULN; ALT, AST (U/L): \>3\*ULN; U/L; bilirubin, direct (mg/dL): \>1.5\*ULN; bilirubin, total (mg/dL): \>2\*ULN; BUN (mg/dL): \>2\*ULN; creatinine (mg/dL): \>1.5\*ULN.

    Time frame: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (±5 days) of follow-up

  2. Summary of Laboratory Marked Abnormalities in Electrolyte and Other Clinical Test Results During the Treatment Period (Patients With Available Measurements)

    preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Calcium, total (mg/dL): \<0.8\*LLN or \>1.2\*ULN, or if preRx\<LLN use \<0.75\*preRx or \>ULN if preRx \>ULN use \>1.25\*preRx or \<LLN; chloride, serum (mEq/L): \<0.9\*LLN or \>1.1\*ULN, or if preRx\<LLN use \<0.9\*preRx or \>ULN if preRx\>ULN use \>1.1\*preRx or \<LLN; bicarbonate (mEq/L): \<0.75\*LLN or \>1.25\*ULN, or if preRx \< LLN use \<0.75\*preRx or \>ULN if preRx \>ULN use \>1.25\*preRx or \< LLN; potassium, serum (mEq/L): \<0.9\* LLN or \>1.1\*ULN, or if preRx\<LLN use \<0.9 \*preRx or \>ULN if preRx\>ULN use \>1.1\*preRx or \<LLN; sodium, serum (mEq/L): \<0.95\*LLN or \>1.05\*ULN, or if preRx \<LLN use \<0.95\*preRx or \>ULN if preRx\>ULN use \>1.05\*preRx or \<LLN; protein, total (g/dL): \<0.9\*LLN or \>1.1\*ULN, or if preRx \<LLN use 0.9\*preRx or \>ULN if preRx \>ULN use 1.1\*preRx or \<LLN; CK (U/L): \>5\*ULN; uric acid (mg/dL): \>1.5\*ULN, or if preRx \>ULN use \>2\*preRx; glucose, fasting serum (mg/dL): \<0.8\*LLN or \>1.5\*ULN, or if preRx \<LLN use \<0.8\*preRx or \>ULN.

    Time frame: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (±5 days) of follow-up

  3. Summary of Laboratory Marked Abnormalities in Urinalysis Results During the Treatment Period-Treated Subjects With Available Measurements (Urinalysis)

    preRX=pretreatment. Blood, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; glucose, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; protein, urine: If missing preRx use ≥ 2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; Red blood cells , urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; white blood cells, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4.

    Time frame: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (± 5 days) of follow-up

07

Results

Posted May 13, 2014

Participant flow

Participant flow — Overall Study
MilestoneApixaban, 2.5 mg BID + PlaceboEnoxaparin, 40 mg QD + Placebo
Started15281529
Received treatment15011508
Evaluable participants907921
Primary participants976997
Completed13921393
Not completed136136
Withdrew: Death10
Withdrew: Adverse event4044
Withdrew: Withdrawal by subject6857
Withdrew: Lost to follow-up10
Withdrew: Poor compliance/noncompliance12
Withdrew: No longer met study criteria1822
Withdrew: Other711

Outcome measures

SecondaryRate of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During the Intended Treatment Period

Event rate=Number of events divided by the number of patients evaluated. Intended treatment period starts on the day of randomization, and for those who received study drug, ends at the later of 2 days after last dose or 14 days after the first dose of study drug; for randomized patients who did not receive study drug, the period ends 14 days after randomization; for randomized patients who did not receive study drug, the period ends 14 days after randomization. Venous thromboembolic event (VTE)=nonfatal pulmonary embolism (PE), symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death=fatal PE or sudden death for which VTE could not be excluded as a cause.

Time frame:
Day of randomization to later of 2 days after last dose or 14 days after first dose; 14 days after randomization for those who did not receive study
Reported as:
Number · Percentage of events/patients evaluated
Rate of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During the Intended Treatment Period
Percentage of events/patients evaluatedApixaban, 2.5 mg BID + PlaceboEnoxaparin, 40 mg QD + Placebo
Rate of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During the Intended Treatment Period1.09 (0.62 to 1.88)2.17 (1.47 to 3.18)
Statistical analysis
  • Apixaban, 2.5 mg BID + Placebo vs Enoxaparin, 40 mg QD + Placebo · Yanagawa, Tango, and Hiejima test · p = 0.0003 (1-sided P-value) · Risk ratio (rr): .50Apixaban-enoxaparin
  • Apixaban, 2.5 mg BID + Placebo vs Enoxaparin, 40 mg QD + Placebo · Inverse variance method · Risk difference (rd): -1.04 · 95% CI -2.03 to -0.05
SecondaryRate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), and Major Bleeding or CRNM

Event rate=Number of events divided by number of patients evaluated. Adjusted difference of event rates takes into consideration type of surgery as a stratification factor. Bleeding Criteria: Major bleeding=an event consisting of clinically overt bleeding accompanied by a decrease in hemoglobin of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. CRNM bleeding= clinically overt bleeding; that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event; that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding; or a change in antithrombic treatment.

Time frame:
Days 1 to 12
Reported as:
Number · Percentage of events/patients evaluated
Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), and Major Bleeding or CRNM
Percentage of events/patients evaluatedApixaban, 2.5 mg BID + PlaceboEnoxaparin, 40 mg QD + Placebo
Major bleeding (n=9, 14)0.60 (0.30 to 1.16)0.93 (0.54 to 1.57)
CRNM (n=44, 58)2.93 (2.19 to 3.93)3.85 (2.98 to 4.95)
Major bleeding or CRNM (n=53, 72)3.53 (2.71 to 4.60)4.77 (3.81 to 5.98)
Any bleeding6.93 (5.75 to 8.34)8.36 (7.06 to 9.87)
Statistical analysis
  • Apixaban, 2.5 mg BID + Placebo vs Enoxaparin, 40 mg QD + Placebo · Mantel Haenszel · p = 0.3014 · Adjusted difference of event rates: -0.33 · 95% CI -0.95 to 0.29Apixaban-enoxaparin
  • Apixaban, 2.5 mg BID + Placebo vs Enoxaparin, 40 mg QD + Placebo · Mantel Haenszel · p = 0.1668 · Adjusted difference of event rates: -0.91 · 95% CI -2.20 to 0.38Apixaban-enoxaparin
  • Apixaban, 2.5 mg BID + Placebo vs Enoxaparin, 40 mg QD + Placebo · Mantel Haenszel · p = 0.0881 · Adjusted difference of event rates: -1.24 · 95% CI -2.66 to 0.18Apixaban-enoxaparin
  • Apixaban, 2.5 mg BID + Placebo vs Enoxaparin, 40 mg QD + Placebo · Mantel Haenszel · p = 0.1412 · Adjusted difference of event rates: -1.39 · 95% CI -3.29 to 0.51Apixaban-enoxaparin
PrimaryRate of Adjudicated Venous Thromboembolic Event-related and All-cause Deaths With Onset During the Intended-treatment Period

Event rate=Number of events divided by the number of patients evaluated. Intended treatment period starts on the day of randomization, and for those who received study drug, ends at the later of 2 days after last dose or 14 days after the first dose of study drug; for randomized patients who did not receive study drug, the period ends 14 days after randomization.Venous thromboembolic event (VTE)=nonfatal pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), or asymptomatic proximal DVT detected by ultrasound. VTE-related death=fatal PE or sudden death for which VTE could not be excluded as a cause.

Time frame:
Day of randomization to later of 2 days after last dose or 14 days after first dose; 14 days after randomization for those who did not receive study drug
Reported as:
Number · Percentage of events/patients evaluated
Rate of Adjudicated Venous Thromboembolic Event-related and All-cause Deaths With Onset During the Intended-treatment Period
Percentage of events/patients evaluatedApixaban, 2.5 mg BIDEnoxaparin, 40 mg QD
Rate of Adjudicated Venous Thromboembolic Event-related and All-cause Deaths With Onset During the Intended-treatment Period15.06 (12.95 to 17.46)24.37 (21.81 to 27.14)
Statistical analysis
  • Apixaban, 2.5 mg BID vs Enoxaparin, 40 mg QD · Yanagawa, Tango, and Hiejima test · p = <0.0001 (P-value was statistically significant at the 1-sided 0.025 level) · Risk ratio (rr): 0.62 · 95% CI 0.51 to 0.74Apixaban-enoxaparin
  • Apixaban, 2.5 mg BID vs Enoxaparin, 40 mg QD · Yanagawa, Tango, and Hiejima test · p = <0.0001 (P-value is statistically significant at the 1-sided 0.025 level) · Risk difference (rd): -9.27 · 95% CI -12.74 to -5.79Apixaban-enoxaparin
SecondaryNumber of Participants With Serious Adverse Events (SAE), Bleeding Adverse Events (AEs), Discontinuations Due to AEs, and Death as Outcome

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Bleeding AEs=all serious or nonserious bleeding-related AEs.

Time frame:
Days 1 through 12 + 2 days (nonserious AEs, bleeding AES) or 30 days (SAES, deaths) after last dose of study drug
Reported as:
Number · Participants
Number of Participants With Serious Adverse Events (SAE), Bleeding Adverse Events (AEs), Discontinuations Due to AEs, and Death as Outcome
ParticipantsApixaban, 2.5 mg BID + PlaceboEnoxaparin, 40 mg QD + Placebo
SAE7288
Bleeding AE90112
Discontinuations due to AEs4044
Deaths20
Other pre-specifiedSummary of Laboratory Marked Abnormalities on Hematology and Liver and Kidney Function Test Results During the Treatment Period (Patients With Available Measurements)

preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal; abs=absolute. Hemoglobin (g/dL): \>2 decrease from preRx value or value \<=8; hematocrit (%): \<0.75\*preRx; platelets: \<100\*10\^9 cells/L; erythrocytes (\*10\^6 cells/μL): \<0.75\*preRx; leukocytes: \<0.75\*LLN or \>1.25\*ULN, or if preRx \<LLN, use \<0.8\*preRx or \>ULN if preRx \>ULN use \>1.2\*preRx or \<LLN; abs basophils: \>400/mm\^3; abs eosinophils: \> 0.750\*10\^3 cells/µL; abs lymphocytes: \<0.750\*10\*3 cells/ µL or \>7.50\*10\^3 c/ µL; abs monocytes \> 2000/mm\^3; abs neutrophils: \<1.0\*10\^3 cells/μL; ALP (U/L): \>2\*ULN; ALT, AST (U/L): \>3\*ULN; U/L; bilirubin, direct (mg/dL): \>1.5\*ULN; bilirubin, total (mg/dL): \>2\*ULN; BUN (mg/dL): \>2\*ULN; creatinine (mg/dL): \>1.5\*ULN.

Time frame:
Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (±5 days) of follow-up
Reported as:
Number · Participants
Summary of Laboratory Marked Abnormalities on Hematology and Liver and Kidney Function Test Results During the Treatment Period (Patients With Available Measurements)
ParticipantsApixaban, 2.5 mg BID + PlaceboEnoxaparin, 40 mg QD + Placebo
Hemoglobin, low (n=1424, 1442)11271178
Hematocrit, low n=(1369, 1396)668723
Platelet count, low (n=1413, 1425)75
Erythrocytes, low (n=1368, 1396)690735
Leukocytes, low (n=1457, 1471)2726
Leukocytes, high (n=1457, 1471)193213
Basophils (absolute), high (n=1448, 1465)24
Eosinophils (absolute), high (n=1448, 1465)4360
Lymphocytes (absolute), low (n=1448, 1465)203215
Lymphocytes (absolute), high (n=1448, 1465)10
Monocytes (absolute), high (n=1448, 1465)52
Neutrophils (absolute), low (n=1448, 1465)52
Alkaline phosphatase (ALP), high (n=1465, 1476)1531
Alanine aminotransferase (ALT), high (n=1459,1472)3226
Aspartate aminotransferase (AST) , high (n=1459,143426
Bilirubin, direct (high) (n=1447,1457)8776
Bilirubin, total (high) (n=1461,1476)159
Blood urea nitrogen (BUN) (high)(n=1447,1458)1517
Creatinine (high) (n=1447,1458)1723
Other pre-specifiedSummary of Laboratory Marked Abnormalities in Electrolyte and Other Clinical Test Results During the Treatment Period (Patients With Available Measurements)

preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Calcium, total (mg/dL): \<0.8\*LLN or \>1.2\*ULN, or if preRx\<LLN use \<0.75\*preRx or \>ULN if preRx \>ULN use \>1.25\*preRx or \<LLN; chloride, serum (mEq/L): \<0.9\*LLN or \>1.1\*ULN, or if preRx\<LLN use \<0.9\*preRx or \>ULN if preRx\>ULN use \>1.1\*preRx or \<LLN; bicarbonate (mEq/L): \<0.75\*LLN or \>1.25\*ULN, or if preRx \< LLN use \<0.75\*preRx or \>ULN if preRx \>ULN use \>1.25\*preRx or \< LLN; potassium, serum (mEq/L): \<0.9\* LLN or \>1.1\*ULN, or if preRx\<LLN use \<0.9 \*preRx or \>ULN if preRx\>ULN use \>1.1\*preRx or \<LLN; sodium, serum (mEq/L): \<0.95\*LLN or \>1.05\*ULN, or if preRx \<LLN use \<0.95\*preRx or \>ULN if preRx\>ULN use \>1.05\*preRx or \<LLN; protein, total (g/dL): \<0.9\*LLN or \>1.1\*ULN, or if preRx \<LLN use 0.9\*preRx or \>ULN if preRx \>ULN use 1.1\*preRx or \<LLN; CK (U/L): \>5\*ULN; uric acid (mg/dL): \>1.5\*ULN, or if preRx \>ULN use \>2\*preRx; glucose, fasting serum (mg/dL): \<0.8\*LLN or \>1.5\*ULN, or if preRx \<LLN use \<0.8\*preRx or \>ULN.

Time frame:
Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (±5 days) of follow-up
Reported as:
Number · Participants
Summary of Laboratory Marked Abnormalities in Electrolyte and Other Clinical Test Results During the Treatment Period (Patients With Available Measurements)
ParticipantsApixaban, 2.5 mg BID + PlaceboEnoxaparin, 40 mg QD + Placebo
Calcium, total (low) (n=1447, 1457)59
Chloride, serum (low)(n=1442, 1454)10
Bicarbonate (low) (n=1435, 1447)03
Potassium, serum (low) (n=1438, 1453)3841
Potassium, serum (high)(n=1438, 1453)3440
Sodium, serum (low) (n=1442, 1454)510
Sodium, serum (high) (n=1442, 1454)10
Glucose, fasting serum (low) (n=715, 713)81
Glucose, fasting serum (high) (n=715, 713)4625
Protein, total (low) (n=1447, 1457223243
Creatine kinase (CK) (high) (n=1463, 1476)6665
Uric acid (high) (n=1446, 1458)12
Other pre-specifiedSummary of Laboratory Marked Abnormalities in Urinalysis Results During the Treatment Period-Treated Subjects With Available Measurements (Urinalysis)

preRX=pretreatment. Blood, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; glucose, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; protein, urine: If missing preRx use ≥ 2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; Red blood cells , urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; white blood cells, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4.

Time frame:
Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (± 5 days) of follow-up
Reported as:
Number · Participants
Summary of Laboratory Marked Abnormalities in Urinalysis Results During the Treatment Period-Treated Subjects With Available Measurements (Urinalysis)
ParticipantsApixaban, 2.5 mg BID + PlaceboEnoxaparin, 40 mg QD + Placebo
Blood, urine (high) (n=1421, 1430)169113
Glucose, urine (high) (n=1421, 1429)160154
Protein, urine (high) (n=1421, 1430)6089
Red blood cells, urine (high) (n=441, 385)133116
White blood cells, urine (high)(n=441, 386)101102

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apixiban, 2.5 mg BID Plus Placebo—72/1,501 (4.8%)295/1,501 (19.7%)
Enoxaparin, 40 mg QD Plus Placebo—88/1,508 (5.8%)342/1,508 (22.7%)
Most frequent serious events
Showing 10 of 107
Most frequent serious events
EventApixiban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus Placebo
Deep vein thrombosisVascular disorders11/150122/1508
Pulmonary embolismRespiratory, thoracic and mediastinal disorders5/15011/1508
Atrial fibrillationCardiac disorders1/15015/1508
HaemorrhageVascular disorders4/15013/1508
Wound infectionInfections and infestations2/15014/1508
Postoperative wound infectionInfections and infestations3/15011/1508
Oedema peripheralGeneral disorders2/15012/1508
Wound haemorrhageVascular disorders2/15010/1508
AnaemiaBlood and lymphatic system disorders2/15011/1508
ErysipelasInfections and infestations2/15011/1508
Most frequent other events
Most frequent other events
EventApixiban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus Placebo
Deep vein thrombosisVascular disorders92/1501130/1508
NauseaGastrointestinal disorders102/1501120/1508
VomitingGastrointestinal disorders77/150188/1508
ConstipationGastrointestinal disorders73/150177/1508

Baseline characteristics

All participants randomized to treatment

Age, Continuous
Age, Continuous(Years)Apixaban, 2.5 mg BID + PlaceboEnoxaparin, 40 mg QD + PlaceboTotal
Median67 ± 9.8567 ± 9.8267 ± 9.84
Age, Customized
Age, Customized(Participants)Apixaban, 2.5 mg BID + PlaceboEnoxaparin, 40 mg QD + PlaceboTotal
Younger than 65 years6326361268
65 years to younger than 75 years6085761184
75 years and older288317605
Sex: Female, Male
Sex: Female, Male(Participants)Apixaban, 2.5 mg BID + PlaceboEnoxaparin, 40 mg QD + PlaceboTotal
Female108911272216
Male439402841
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Apixaban, 2.5 mg BID + PlaceboEnoxaparin, 40 mg QD + PlaceboTotal
White121612112427
Black/African American141731
Asian252254506
Native Hawaiian/Other Pacific Islander112
Other [Not specified]454691
Hispanic/Latino011
Not Hispanic/Latino5357110
Ethnicity not reported147514712946
Region of Enrollment
Region of Enrollment(Participants)Apixaban, 2.5 mg BID + PlaceboEnoxaparin, 40 mg QD + PlaceboTotal
Philippines121426
Spain6160121
Ukraine181182363
Russian Federation150156306
Israel434386
Chile156
Colombia363571
Italy6969138
India9292184
France7268140
Malaysia448
Denmark262349
South Africa5656112
China9090180
Korea, Republic of403878
Austria156151307
United Kingdom6361124
Czech Republic485098
Hungary171936
Mexico6059119
Belgium272552
Brazil171734
Poland414586
Singapore8917
Norway353671
Germany122122244
Sweden101
Type of Risk Factor
Type of Risk Factor(Participants)Apixaban, 2.5 mg BID + PlaceboEnoxaparin, 40 mg QD + PlaceboTotal
Knee replacement257286543
Hip replacement9080170
Hip or knee fracture surgery5549104
Deep vein thrombosis363268
Pulmonary embolism101020
08

Study locations

122 sites
  • Local Institution
    Graz, 8036, Austria
  • Local Institution
    Innsbruck, 6020, Austria
  • Local Institution
    Linz, 4010, Austria
  • Local Institution
    Wels, 4600, Austria
  • Local Institution
    Wiener Neustadt, 2700, Austria
  • Local Institution
    Wien, 1090, Austria
  • Local Institution
    Wien, 1130, Austria
  • Local Institution
    Antwerpen, 2020, Belgium
  • Local Institution
    Hasselt, 3500, Belgium
  • Local Institution
    Belo Horizonte - Mg, Minas Gerais 30130, Brazil
  • Local Institution
    Sao Paulo, 04023, Brazil
  • Local Institution
    Santiago, Metropolitana 7500922, Chile
  • Local Institution
    Santiago, Metropolitana 8330033, Chile
  • Local Institution
    Beijing, Beijing 100035, China
  • Local Institution
    Beijing, Beijing 100835, China
  • Local Institution
    Qingdao, Shandong 266003, China
  • Local Institution
    Shanghai, Shanghai 200011, China
  • Local Institution
    Shanghai, Shanghai 200025, China
  • Local Institution
    Shanghai, Shanghai 200233, China
  • Local Institution
    Bogota, XXXXX, Colombia
  • Local Institution
    Bogota, Colombia
  • Local Institution
    Cali, - - - - -, Colombia
  • Local Institution
    Medelin, Colombia
  • Local Institution
    Brno, 662 50, Czech Republic
  • Local Institution
    Chomutov, 430 12, Czech Republic
  • Local Institution
    Pardubice, 532 03, Czech Republic
  • Local Institution
    Prague 8, 180 81, Czech Republic
  • Local Institution
    Uherske Hradiste, 686 68, Czech Republic
  • Local Institution
    Hellerup, 2900, Denmark
  • Local Institution
    Hvidovre, 2650, Denmark
  • Local Institution
    Kolding, 6000, Denmark
  • Local Institution
    Viborg, 8800, Denmark
  • Local Institution
    Monaco, 98000, France
  • Local Institution
    Nice, 06200, France
  • Local Institution
    Paris, 75014, France
  • Local Institution
    Paris, 75019, France
  • Local Institution
    Paris, 75679, France
  • Local Institution
    Saint-Saulve, 59880, France
  • Local Institution
    Bad Mergentheim, 97980, Germany
  • Local Institution
    Bochum, 44791, Germany
  • Local Institution
    Brandenburg, 14770, Germany
  • Local Institution
    Dresden, 01307, Germany
  • Local Institution
    Frankfurt Am Main, 60528, Germany
  • Local Institution
    Frankfurt, 65929, Germany
  • Local Institution
    Halle/S, 06112, Germany
  • Local Institution
    Kremmen Ot Sommerfeld, 16766, Germany
  • Local Institution
    Rheinfelden, 79618, Germany
  • Local Institution
    Witten, 58455, Germany
  • Local Institution
    Szeged, 6725, Hungary
  • Local Institution
    Szekszard, 7100, Hungary
  • Local Institution
    Ahmedabad, Gujarat 380054, India
  • Local Institution
    Ludhiana, Punjab 141001, India
  • Local Institution
    Bangalore, 560034, India
  • Local Institution
    Baroda, 390007, India
  • Local Institution
    Mangalore, 575001, India
  • Local Institution
    Jeruselem, 91031, Israel
  • Local Institution
    Petach-Tikva, 49372, Israel
  • Local Institution
    Safed, 13110, Israel
  • Local Institution
    Tel Aviv, 64239, Israel
  • Local Institution
    Tel Hashomer, 52621, Israel
  • Local Institution
    Abano Terme (Pd), 35031, Italy
  • Local Institution
    Bologna, 40136, Italy
  • Local Institution
    Pordenone, 33170, Italy
  • Local Institution
    Roma, 00168, Italy
  • Local Institution
    San Donato Milanese (Mi), 20097, Italy
  • Local Institution
    Jeonnam, 519-809, Korea, Republic of
  • Local Institution
    Seoul, 110-744, Korea, Republic of
  • Local Institution
    Seoul, 136-705, Korea, Republic of
  • Local Institution
    Seoul, 138-736, Korea, Republic of
  • Local Institution
    Kuala Lumpur, 50586, Malaysia
  • Local Institution
    Kuala Lumpur, 56000, Malaysia
  • Local Institution
    Zapopan, Jalisco 45200, Mexico
  • Local Institution
    Hermosillo, Sonora 83190, Mexico
  • Local Institution
    Aguascalientes, 20010, Mexico
  • Local Institution
    San Luis Potosi, 78340, Mexico
  • Local Institution
    Veracruz, 91700, Mexico
  • Local Institution
    Alesund, 6026, Norway
  • Local Institution
    Gjettum, 1346, Norway
  • Local Institution
    Kongsvinger, 2212, Norway
  • Local Institution
    Manila, 1000, Philippines
  • Local Institution
    Quezon City, 1102, Philippines
  • Local Institution
    Quezon City, 1114, Philippines
  • Local Institution
    Bytom, 41-902, Poland
  • Local Institution
    Gdansk, 80-803, Poland
  • Local Institution
    Warszawa, 03-242, Poland
  • Local Institution
    Wroclaw, 50-556, Poland
  • Local Institution
    Chelyabinsk, 454021, Russian Federation
  • Local Institution
    Kazan, 420029, Russian Federation
  • Local Institution
    Lipetsk, 398035, Russian Federation
  • Local Institution
    Moscow, 115522, Russian Federation
  • Local Institution
    Rostov-Na-Donu, 344010, Russian Federation
  • Local Institution
    Saint Petersburg, 193312, Russian Federation
  • Local Institution
    Saint Petersburg, 194354, Russian Federation
  • Local Institution
    Saint Petersburg, 195427, Russian Federation
  • Local Institution
    Saint Petersburg, 199106, Russian Federation
  • Local Institution
    Samara, 443095, Russian Federation
  • Local Institution
    Singapore, 169608, Singapore
  • Local Institution
    Singapore, 529889, Singapore
  • Local Institution
    Randburg, Free State 2194, South Africa
  • Local Institution
    Johannesburg, Gauteng 2031, South Africa

Showing the first 100 of 122 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Jamieson MJ, Byon W, Dettloff RW, Crawford M, Gargalovic PS, Merali SJ, Onorato J, Quintero AJ, Russ C. Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data. Am J Cardiovasc Drugs. 2022 Nov;22(6):615-631. doi: 10.1007/s40256-022-00524-x. Epub 2022 May 16. PubMed 35570249 ↗
  • Pineo GF, Gallus AS, Raskob GE, Chen D, Ramirez LM, Ramacciotti E, Lassen MR, Wang L. Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost. 2013 Mar;11(3):444-51. doi: 10.1111/jth.12109. PubMed 23279103 ↗
  • Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 6;375(9717):807-15. doi: 10.1016/S0140-6736(09)62125-5. PubMed 20206776 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 5 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2007
First posted
Mar 27, 2007
Start
Jun 2007
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Results first posted
May 13, 2014
Last update
Jul 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00452530
Responsible party
Sponsor
First posted
Mar 27, 2007
Start date
Jun 2007
Primary completion
Jan 2009
Completion
Jan 2009
Results posted
May 13, 2014
Last update
Jul 9, 2014

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion